Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
The company discovers, designs, and develop its initial programs candidates consists of VMT-α-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.
Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 1983 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Johan Spoor |
Contact Details
Address: 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 United States | |
| Phone | 206 676 0900 |
| Website | perspectivetherapeutics.com |
Stock Details
| Ticker Symbol | CATX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000728387 |
| CUSIP Number | 46489V302 |
| ISIN Number | US46489V3024 |
| Employer ID | 41-1458152 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Johan M. Spoor | Chief Executive Officer and Director |
| Jonathan R. Hunt | Chief Accounting Officer |
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer |
| Juan Graham | Chief Financial Officer |
| Shane Cobb | Executive Vice President of Operations |
| Dr. Michael K. Schultz Ph.D. | Chief Science Officer |
| Annie J. Cheng | Vice President of Investor Relations |
| Andrew Bright | Executive Vice President of Brachytherapy |
| Amos Hedt BA, PGradDip | Chief Business Strategy Officer |
| David Hauser Ph.D. | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 10-K/A | [Amend] Annual report |
| Mar 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | POSASR | Filing |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |